Methods and compositions for tumor immunotherapy using patient-derived immune cell products and il-15 superagonists
By combining patient-derived immune cell products and IL-15 superagonists, the method addresses immune evasion in MHC-I negative tumors, converting them into responsive 'hot' tumors and restoring checkpoint inhibitor efficacy.
WO2026076014A1 Publication Date: 2026-04-09NANT HOLDINGS IP LLC
1 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/048797
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-30
- Filing Date
- 2025-09-30
- Publication Date
- 2026-04-09
AI Technical Summary
Technical Problem
Existing cancer immunotherapies face limitations in treating MHC-I negative tumors due to immune evasion, poor persistence of immune cells, and resistance to checkpoint inhibitors, with iNKT cells being difficult to expand and maintain functionality for clinical use.
Method used
Combining patient-derived immune cell products with IL-15 superagonists and preconditioning regimens to enhance NK and iNKT cell activation, restoring MHC-I expression in tumors and converting 'cold' tumors into 'hot' tumors responsive to checkpoint inhibitors.
Benefits of technology
The approach induces durable and synergistic immune responses, enhancing NK and T cell activity, and restoring sensitivity to checkpoint inhibitors, even in tumors resistant to conventional therapies.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are methods, compositions, and kits for treating tumors by combining patient-derived immune effector cells with cytokine and therapeutic agents. In one aspect, apheresis material is processed to isolate at least two products selected from T cell, NK cell, and dendritic cell populations, which are formulated and administered to the patient. In another aspect, invariant natural killer T (iNKT) cells are expanded ex vivo using an IL-15:IL-15Rα complex and α-galactosylceramide delivered on a bacterial minicell nanoparticle, enabling scalable production of functional cells. Additional embodiments include tumor microenvironment preconditioning regimens and use of IL-15 superagonists to convert "cold" tumors into "hot" tumors.
Need to check novelty before this filing date? Find Prior Art